Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 6.69%25.68B | 12.82%133.7B | 11.08%24.07B | 12.29%118.51B | 14.23%39.63B | 11.95%30.15B | 14.61%27.07B | 6.72%21.67B | -6.53%105.54B | -1.37%34.69B |
| Cost of revenue | 8.74%18.24B | 10.39%87.24B | 8.82%16.78B | 11.82%79.03B | 13.16%23.77B | 12.93%20.83B | 15.71%19.02B | 4.22%15.42B | -4.68%70.68B | -2.40%21.01B |
| Gross profit | 2.00%7.44B | 17.68%46.45B | 16.64%7.29B | 13.24%39.47B | 15.87%15.86B | 9.82%9.32B | 12.10%8.05B | 13.43%6.25B | -10.07%34.86B | 0.26%13.68B |
| Operating expense | 12.82%7.65B | 10.67%30.77B | 6.22%6.78B | 7.04%27.8B | 11.01%7.66B | 6.80%7.34B | 4.50%6.42B | 5.38%6.39B | -0.57%25.98B | -9.15%6.9B |
| Staff costs | ---- | 10.60%17.16B | ---- | 3.95%15.51B | ---- | ---- | ---- | ---- | 0.57%14.92B | ---- |
| Selling and administrative expenses | ---- | 22.93%2.55B | ---- | 7.51%2.08B | ---- | ---- | ---- | ---- | 3.54%1.93B | ---- |
| -General and administrative expense | ---- | 22.93%2.55B | ---- | 7.51%2.08B | ---- | ---- | ---- | ---- | 3.54%1.93B | ---- |
| Research and development costs | ---- | 10.79%2.68B | ---- | 3.20%2.42B | ---- | ---- | ---- | ---- | -5.60%2.35B | ---- |
| Depreciation and amortization | ---- | 12.57%1.17B | ---- | 6.87%1.04B | ---- | ---- | ---- | ---- | 0.83%975M | ---- |
| -Depreciation | ---- | 8.87%1.12B | ---- | 6.99%1.03B | ---- | ---- | ---- | ---- | 0.31%959M | ---- |
| -Amortization | ---- | 250.00%56M | ---- | 0.00%16M | ---- | ---- | ---- | ---- | 45.45%16M | ---- |
| Rent and land expenses | ---- | 11.65%1.97B | ---- | 10.14%1.76B | ---- | ---- | ---- | ---- | 4.31%1.6B | ---- |
| Other operating expenses | ---- | 5.03%5.25B | ---- | 18.79%5B | ---- | ---- | ---- | ---- | -5.27%4.21B | ---- |
| Operating profit | -142.80%-217M | 34.38%15.68B | 472.79%507M | 31.35%11.67B | 20.82%8.19B | 22.69%1.98B | 57.02%1.63B | 75.27%-136M | -29.71%8.88B | 12.08%6.78B |
| Net non-operating interest income (expenses) | -50.00%-3M | 12M | 50.00%-2M | 0 | 20.00%6M | -300.00%-2M | 0 | -500.00%-4M | -23.08%10M | -37.50%5M |
| Non-operating interest income | 50.00%3M | 88.24%32M | --2M | -22.73%17M | 11.11%10M | -50.00%3M | -20.00%4M | --0 | 0.00%22M | -18.18%9M |
| Non-operating interest expense | 50.00%6M | 17.65%20M | 0.00%4M | 41.67%17M | 0.00%4M | 0.00%5M | 100.00%4M | 300.00%4M | 33.33%12M | 33.33%4M |
| Net investment income | 22.78%97M | -5.79%114M | 16.18%79M | 10.00%121M | -50.00%19M | 0.00%22M | 1,100.00%12M | 38.78%68M | 66.67%110M | 100.00%38M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 461.11%303M | -59.70%54M | -46.53%54M | 0 | 930.77%134M | 676.92%101M | ||||
| Income from associates and other participating interests | 269.44%133M | -5.97%331M | -44.62%36M | 16.94%352M | 21.26%154M | -24.42%65M | 94.29%68M | 22.64%65M | 5.24%301M | 28.28%127M |
| Special income (charges) | -3M | -2,204.76%-484M | 0 | -103.11%-21M | -5.00%-21M | -100.25%-2M | 97.59%-2M | 130.77%4M | 22,433.33%676M | -300.00%-20M |
| Less:Other special charges | --3M | 33.33%28M | ---- | 103.11%21M | ---- | ---- | -97.59%2M | -130.77%-4M | -2,314.29%-676M | 200.00%20M |
| Less:Write off | ---- | --456M | ---- | --0 | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non-operating income (expenses) | 20.69%35M | 10.75%103M | -6.45%29M | 0.00%93M | 110.00%42M | -71.88%9M | -42.11%11M | 40.91%31M | -34.51%93M | 150.00%20M |
| Income before tax | -93.52%42M | 30.91%16.05B | 2,134.48%648M | 20.18%12.26B | 19.78%8.44B | -18.50%2.07B | 69.75%1.72B | 107.29%29M | -22.43%10.2B | 13.96%7.05B |
| Income tax | -39.80%180M | 39.92%5.39B | 346.27%299M | 20.62%3.86B | 18.21%2.59B | -8.18%662M | 63.91%536M | 255.81%67M | -17.78%3.2B | 27.68%2.19B |
| Net income | -139.54%-138M | 26.80%10.66B | 1,043.24%349M | 19.98%8.41B | 20.47%5.85B | -22.55%1.41B | 72.63%1.19B | 89.55%-37M | -24.39%7.01B | 8.68%4.86B |
| Net income continuous operations | -139.54%-138M | 26.78%10.66B | 1,018.42%349M | 19.98%8.41B | 20.49%5.85B | -22.59%1.41B | 72.53%1.19B | 89.30%-38M | -24.38%7.01B | 8.68%4.86B |
| Noncontrolling interests | -63.64%-36M | -163.86%-438M | 37.14%-22M | -1,085.71%-166M | -331.25%-74M | -277.78%-48M | 75.68%-9M | 2.78%-35M | 83.33%-14M | 184.21%32M |
| Net income attributable to the company | -127.22%-101M | 29.44%11.1B | 18,650.00%371M | 22.10%8.57B | 22.80%5.92B | -18.69%1.46B | 65.06%1.2B | 99.37%-2M | -24.91%7.02B | 7.06%4.82B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -127.22%-101M | 29.44%11.1B | 18,650.00%371M | 22.10%8.57B | 22.80%5.92B | -18.69%1.46B | 65.06%1.2B | 99.37%-2M | -24.91%7.02B | 7.06%4.82B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -127.72%-1.73 | 32.20%187.86 | 15,700.00%6.24 | 22.06%142.1 | 22.76%98.18 | -18.72%24.14 | 64.89%19.82 | 99.24%-0.04 | -24.92%116.42 | 7.04%79.98 |
| Diluted earnings per share | -127.72%-1.73 | 32.20%187.86 | 15,700.00%6.24 | 22.06%142.1 | 22.79%98.1786 | -18.72%24.14 | 65.01%19.8069 | 99.24%-0.04 | -24.92%116.42 | 7.03%79.9569 |
| Dividend per share | 0 | 43.40%76 | 0 | 32.50%53 | 50.00%30 | 0 | 15.00%23 | 0 | 11.11%40 | 11.11%20 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |